An Exploratory Study to Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs.
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2017
At a glance
- Drugs Nivolumab (Primary) ; Ipilimumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.
- 15 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
- 22 Jan 2016 Protocol has been amended with addition of Ipilimumab as reported by ClinicalTrials.gov.